| [1] |
Walsh G.Biopharmaceutical benchmarks 2014[J].Nat Biotechnol,2014,32(10):992-1000.
|
| [2] |
Zundorf I,Dingermann T.PEGylation—a well-proven strategy for the improvement of recombinant drugs[J].Pharmazie,2014,69(5):323-326.
|
| [3] |
Ginn C,Khalili H,Lever R,et al.PEGylation and its impact on the design of new protein-based medicines[J].Fut Med Chem,2014,6(16):1829-1846.
|
| [4] |
Turecek PL,Bossard MJ,Schoetens F,et al.PEGylation of biopharmaceuticals:a review of chemistry and nonclinical safety information of approved drugs[J].J Pharm Sci,2016,105(2):460-475.
|
| [5] |
Garay RP,El-Gewely R,Armstrong JK,et al.Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents[J].Exp Opin Drug Deliv,2012,9(11):1319-1323.
|
| [6] |
Ishida T,Kiwada H.Anti-polyethyleneglycol antibody response to PEGylated substances[J].Biol Pharm Bull,2013,36(6):889-891.
|
| [7] |
Verhoef JJ,Carpenter JF,Anchordoquy TJ,et al.Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics[J].Drug Discov Today,2014,19(12):1945-1952.
|
| [8] |
Zhang F,Liu MR,Wan HT.Discussion about several potential drawbacks of PEGylated therapeutic proteins[J].Biol Pharm Bull,2014,37(3):335-339.
|
| [9] |
Freire-de-Lima L,Fonseca LM,Oeltmann T,et al.The trans-sialidase,the major trypanosoma cruzi virulence factor:three decades of studies[J].Glycobiology,2015,25(11):1142-1149.
|
| [10] |
Buscaglia CA,Alfonso J,Campetella O,et al.Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood[J].Blood,1999,93(6):2025-2032.
|
| [11] |
Alvarez P,Buscaglia CA,Campetella O.Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences[J].J Biol Chem,2004,279(5):3375-3381.
|
| [12] |
Liu D,Nikoo M,Boran G,et al.Collagen and gelatin[J].Annu Rev Food Sci Technol,2015,6:527-557.
|
| [13] |
Huang YS,Wen XF,Wu YL,et al.Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer[J].Eur J Pharm Bio-pharm,2010,74(3):435-441.
|
| [14] |
Roberts S,Dzuricky M,Chilkoti A.Elastin-like polypeptides as models of intrinsically disordered proteins[J].FEBS Lett,2015,589(19):2477-2486.
|
| [15] |
Kowalczyk T,Hnatuszko-Konka K,Gerszberg A,et al.Elastin-like polypeptides as a promising family of genetically-engineered protein based polymers[J].World J Microbiol Biotechnol,2014,30(8):2141-2152.
|
| [16] |
Ukpebor OT,Shah A,Bazov E,et al.Inverse temperature transition of elastin like motifs in major ampullate dragline silk:MD simulations of short peptides and NMR studies of water dynamics[J].Soft Matter,2014,10(5):773-785.
|
| [17] |
Schipperus R,Eggink G,de Wolf FA.Secretion of elastin-like polypeptides with different transition temperatures by Pichia pastoris[J].Biotechnol Prog,2012,28(1):242-247.
|
| [18] |
Bataille L,Dieryck W,Hocquellet A,et al.Recombinant production and purification of short hydrophobic Elastin-like polypeptides with low transition temperatures[J].Protein Exp Purif,2016,121:81-87.
|
| [19] |
Hu J,Wang G,Liu X,et al.Enhancing pharmacokinetics,tumor accumulation,and antitumor efficacy by alastin-Like polypeptide fusion of interferon alpha[J].Adv Mater,2015,27(45):7320-7324.
|
| [20] |
Conrad U,Plagmann I,Malchow S,et al.ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock[J].Plant Biotechnol J,2011,9(1):22-31.
|
| [21] |
Ashutosh C.Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide:US,8178495[P].2012-05-15.
|
| [22] |
Muroga Y,Nakaya A,Inoue A,et al.Conformation of poly(gamma-glutamic acid)in aqueous solution[J].Biopolymers,2016,105(4):191-198.
|
| [23] |
Northfelt DW,Allred JB,Liu HS,et al.Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer[J].Am J Clin Oncol,2014,37(2):167-171.
|
| [24] |
Leung DW.Recombinant production of polyanionic polymers,and uses thereof:US,20020169125[P].2002-10-03.
|
| [25] |
Price JL, Culyba EK, Chen WT, et al. N-glycosylation of enhanced aromatic sequons to increase glycoprotein stability[J].Biopolymers,2012,98(3):195-211.
|
| [26] |
Chung HS,Kim JS,Lee SM,et al.Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats[J].Glycoconj J,2016,33(2):201-208.
|
| [27] |
Besman M.Conjugates of biologically active proteins having a modified in vivo half-life:US,8129348[P].2014-06-10.
|
| [28] |
Schlapschy M,Theobald I,Mack H,et al.Fusion of a recombinant antibody fragment with a homo-amino-acid polymer:effects on biophysical properties and prolonged plasma half-life[J].Protein Eng Des Sel,2007????????ぢ???戩爺??嬳??崸???敢湲搯氾敛爲??吠??牣楨敥摬牬楥据桢????慲椠瑖椬湗敡湮????椬?敥瑥?慨汩???楎??椼杩栾?捴漠湡瑬爮愼猯瑩￣瑁甠浲潥牣?業浢慩杮楡湮杴?睰楯瑬桹?牥慰摴楩潤?氠慥扸整汥敮摤?愠湴瑨楥戠漼摩社??愠扶?晶牯愠朼洯敩渾瑨獡?瑦愭楬汩潦牥攠摯?映潰牥?潴灩瑤楥浳椠穡敮摤?灰桲慯牴浥慩据潳欠楩湮攠瑡椠捴獵?癡楢慬?倠?卡祮汮慥瑲楛潊湝嬮?嵩??楡???扩獯??楣???ぬ????戬????戬?????????〨???戺爱??嬶??崱?‰?愼牢慲爯椾????甠栠湐?乤??扴爠慖济漬療楡捬桡?删??楓?敭琠?慃氬???楥??湡桬愮渼振敩搾?楸??楮湳?癯楮瘠潯??楩??敩普映楶捩慶捯礼?潩显?慨?瑬祦瀭敬???椠湯瑦攠牢晩敯牬潯湧?獣畡灬敬特愠条潣湴楩獶瑥?睭楯瑬桥?敵硬瑥敳渠摢敹搠?灔汅慎猠浰慲?桴慥汩普?汰楯晬敹?楥湲?慛?浝漮甼獩放?洠潃摯敮汴?潯晬?浒略汬瑥楡灳汥攼?獩挾氬攲爰漱猶椬猼孢?崲??椼??￣?椵漲氭??栮敤浯??椱??㈱?????戮??????扬???㈱??㈱?????金?ぢ????戳爱??嬠?づ嵥???潮牧愠瑎桃?噔??潗氬穓数???匠捂桊氬愼灩猾捥桴礠????椯?放瑇?慧氭???楎?偡?匠祩汭慰瑲楯潶湥?漠晧?浵畣牡楧湯敮?汣敡灰瑡楢湬?氠敯慦搠獰?瑥潶?敮硴瑩敮湧搠敨摹?灯汧慬獹浣慥?桩慡氠晷?汴楨景敵?愠湩摮?敲湥桡慳湩据敧搠?楡??楬湩?癥椠癢潬??楤??敬晵晣楯捳慥捛祊孝?崼??楐??潓氠?偮桥愼爯浩??椲??日?????戼??资??戩????????????????扝爠??孬??嵡???潊汌稬敇????潩牮慧琠桎?嘬??慯獲瑥????椼?放瑥?愠污???椯??潁渠杮?慶捥瑬椠湬杯?偧?卡祣汴慩瑮敧搠?汵敭灡瑮椠湧?慯海整汨椠潨牯慲瑭敯獮?漠扦敵獳楩瑯祮?扰祲?灴牥潩浮漨瑖楒湓札″猱愷琩椺敥瑮票?慮湣摥?瀠爼敩瘾敩湮琠楶湩杶?栠礼瀯潩派数瑯慴扥潮汣楹猠浡?楤渠?污敬灦琭楬湩?摥敛晊楝挮椼敩渾瑊??敨灡?潭戠?潣扩?洯楩挾攬嬲?崱??椼??渱搰漱挼爯楢渾漨永漩机礲???椭?祝?????扲??????戠?????㈠???至????批爠??嬬??嵰???慣氠癖漬????呴爠敡浬愮渼琯敩￣????牮捧漭癡楣瑴潩?????業?敮琠?慲汯????楨??浭灯牮潥瘠敷摩?摨漠硤潥牬畡批楥捤椠湣?敥湡捲慡灮獣略氨慖瑒楓漭渳?愷温携?灥桳慵牬浴慳挠潯武椠湡攠瑤楯捵獢?潥昭?晬敩牮牤椬瑰楬湡?晥畢獯椭潣湯?灴牲潯瑬敬楥湤?湳慩湮潧捬慥爠牡楳散牥獮?扩敮慧爠楤湯杳?瀠牳潴汵楤湹攠?獮攠牧楲湯敷?慨渠摨?慲汭慯湮楥渭敤?敦汩散浩敥湮瑴猠孡?嵵??楳??楝漮洼慩挾牊漠浃潬汩敮挠畅汮敤獯??楩????????扢?????戲??社???????土??(6):2595-2603.
|
| [29] |
Alters SE, McLaughlin B, Spink B, et al. GLP2-2G-XTEN:a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn′s disease model[J].PLoS One,2012,7(11):e50630.
|
| [30] |
Haeckel A,Appler F,Figge L,et al.XTEN-annexin A5:XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to PEGylation[J].J Nucl Med,2014,55(3):508-514.
|
| [31] |
Ding S,Song M,Sim BC,et al.Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility[J].Bioconjug Chem,2014,25(7):1351-1359.
|
| [32] |
Schlapschy M,Binder U,Borger C,et al.PASylation:a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins[J].Protein Eng Des Sel,2013,26(
|
下载:
